Trial Profile
The German ADPKD Tolvaptan Treatment Registry is a Prospective, Observational, Multicentric Study of Patients Suffering From ADPKD That Are Considered for Tolvaptan Treatment
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Aug 2023
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Therapeutic Use
- 04 Aug 2023 Planned number of patients changed from 500 to 2000.
- 30 Aug 2018 Planned number of patients changed from 200 to 500.
- 16 Nov 2015 Planned primary completion date changed from 1 Sep 2025 to 1 Nov 2025 as reported by ClinicalTrials.gov record.